Charles Kuzma, MD
Hematology & Oncology · Pinehurst, NCNPI 1063469856
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 21.8%. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $190.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Genentech USA, Inc.$9K
- Incyte Corporation$9K
- GSK$6K
- Coherus Oncology, Inc.$6K
- Beigene USA, Inc.$5K
- plus $24K from 47 others
Across 282 payments — averaging $5769.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$799K
- Pfizer$324K
- Janssen Research & Development, LLC$100K
- E.r. Squibb & Sons, L.L.C.$65K
- Seagen Inc.$61K
- Regeneron$60K
- plus $218K from 14 others
What the payments were for
- Consulting fees$44,22360%
- Speaking & faculty fees$11,02015%
- Travel & lodging$9,94613%
- Food & beverage$8,51911%
- Education$5121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$8,462
- CALQUENCE$6,485
- BRUKINSA$5,344
- BLENREP$3,900
- IMFINZI$3,867
- MONJUVI$3,587
- Oral Paclitaxel$3,500
- Encequidar$3,500
- Cabometyx$2,955
- XPOVIO$2,325
- TAZVERIK$1,441
- Revlimid$1,050
- OJJAARA$650
- XOSPATA$500
- NO PRODUCT DISCUSSED$375
- LIBTAYO$350
- FOUNDATIONONE LIQUID$250
- FOUNDATIONFOCUS$250
- FOUNDATIONONE CDX$250
- FOUNDATIONONE HEME$250
How this compares
$74,220 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 89 | $1,236,919 |
| IbrancePalbociclib | 39 | $582,863 |
| RevlimidLenalidomide | 35 | $575,609 |
| TagrissoOsimertinib Mesylate | 26 | $446,676 |
| CabometyxCabozantinib S-Malate | 15 | $380,189 |
| CalquenceAcalabrutinib Maleate | 23 | $328,354 |
| VerzenioAbemaciclib | 13 | $201,286 |
| ErleadaApalutamide | 14 | $195,584 |
| XtandiEnzalutamide | 14 | $188,615 |
| NubeqaDarolutamide | 13 | $165,879 |
| Abiraterone Acetate | 38 | $100,921 |
| BrukinsaZanubrutinib | 11 | $100,418 |
| EliquisApixaban | 49 | $37,429 |
| XareltoRivaroxaban | 19 | $20,160 |
| Letrozole | 122 | $2,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $16,160 | $775,03049 claims |
| PfizerIbrance, Eliquis | $521 | $620,29288 claims |
| Bristol Myers SquibbRevlimid | $1,557 | $575,60935 claims |
| Exelixis Inc.Cabometyx | $3,367 | $380,18915 claims |
| Johnson & JohnsonErleada, Xarelto | $76 | $215,74433 claims |
| Lilly USA, LLCVerzenio | $369 | $201,28613 claims |
| Astellas Pharma US IncXtandi | $581 | $188,61514 claims |
| BayerNubeqa | $278 | $165,87913 claims |
| Beigene USA, Inc.Brukinsa | $5,108 | $100,41811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Pinehurst
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.